Sysmex (OTCMKTS:SSMXY) Shares Gap Up – Should You Buy?

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s share price gapped up prior to trading on Friday . The stock had previously closed at $11.95, but opened at $12.53. Sysmex shares last traded at $12.43, with a volume of 1,387 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Sysmex from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Sysmex presently has a consensus rating of “Hold”.

Sysmex Stock Performance

The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $7.84 billion, a price-to-earnings ratio of 29.67 and a beta of 1.09. The stock has a fifty day moving average price of $10.62 and a 200-day moving average price of $9.41.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. Sysmex had a return on equity of 7.87% and a net margin of 7.62%.The firm had revenue of $825.85 million for the quarter, compared to analysts’ expectations of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. As a group, analysts anticipate that Sysmex Corporation ADR will post 0.38 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.